|
| related topics |
| {product, liability, claim} |
| {operation, international, foreign} |
| {gas, price, oil} |
| {cost, regulation, environmental} |
| {property, intellectual, protect} |
| {customer, product, revenue} |
| {acquisition, growth, future} |
| {financial, litigation, operation} |
| {product, candidate, development} |
|
|
Competition in seeds and traits and agricultural chemicals has significantly affected, and will continue to affect, our sales.
Efforts to protect our intellectual property rights and to defend claims against us can increase our costs and will not always succeed; any failures could adversely affect sales and profitability or restrict our ability to do business.
We are subject to extensive regulation affecting our seed biotechnology and agricultural products and our research and manufacturing processes, which affects our sales and profitability.
The degree of public acceptance or perceived public acceptance of our biotechnology products can affect our sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.
The degree of public acceptance or perceived public acceptance of our biotechnology products can affect our sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.
The successful development and commercialization of our pipeline products will be necessary for our growth.
Adverse outcomes in legal proceedings could subject us to substantial damages and adversely affect our results of operations and profitability.
Our operations outside the United States are subject to special risks and restrictions, which could negatively affect our results of operations and profitability.
Our operations outside the United States are subject to special risks and restrictions, which could negatively affect our results of operations and profitability.
In the event of any diversion of management s attention to matters related to acquisitions or any delays or difficulties encountered in connection with integrating acquired operations, our business, and in particular our results of operations and financial condition, may be harmed.
Fluctuations in commodity prices can increase our costs and decrease our sales.
Compliance with quality controls and regulations affecting our manufacturing may be costly, and failure to comply may result in decreased sales, penalties and remediation obligations.
Our ability to match our production to the level of product demanded by farmers or our licensed customers has a significant effect on our sales, costs, and growth potential.
Full 10-K form ▸
|
|
| related documents |
| 10456--2/19/2009--BAXTER_INTERNATIONAL_INC |
| 780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 7536--2/8/2008--ARROW_ELECTRONICS_INC |
| 929987--2/22/2006--GUIDANT_CORP |
| 911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 10795--11/24/2010--BECTON_DICKINSON_&_CO |
| 780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 313143--5/27/2008--HAEMONETICS_CORP |
| 874710--9/28/2006--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE |
| 874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 874710--9/28/2007--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 862668--9/29/2008--ESCALON_MEDICAL_CORP |
| 811669--2/24/2006--UST_INC |
| 862668--10/12/2010--ESCALON_MEDICAL_CORP |
| 880432--9/28/2009--MISONIX_INC |
| 1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 736822--7/27/2007--IMMUCOR_INC |
| 10081--2/29/2008--BARR_PHARMACEUTICALS_INC |
| 874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE |
| 882873--9/21/2009--UROLOGIX_INC |
| 811669--2/23/2007--UST_INC |
| 1006045--4/10/2008--IRIDEX_CORP |
| 10456--2/26/2008--BAXTER_INTERNATIONAL_INC |
| 885725--3/1/2006--BOSTON_SCIENTIFIC_CORP |
| 768408--6/24/2010--CYANOTECH_CORP |
| 739944--3/15/2007--MEDTOX_SCIENTIFIC_INC |
| 275053--3/16/2010--NATURES_SUNSHINE_PRODUCTS_INC |
| 57528--2/22/2008--LANCE_INC |
|